Short-term inverse-agonist treatment induces reciprocal changes in δ-opioid agonist and inverse-agonist binding capacity

Molecular Pharmacology

Volumn 60, Issue 4, 2001, Pages 816-827

  Piñeyro, Graciela ^a   Azzi, Mounia ^a   De Léan, André ^a   Schiller, Peter ^b   Bouvier, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREMAZOCINE; DELTA OPIATE RECEPTOR AGONIST; ENKEPHALIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLYLIMIDODIPHOSPHATE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALTRINDOLE; PERTUSSIS TOXIN; PHENYLALANINE; RECEPTOR PROTEIN; TYROSINE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; ISOMERISM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034806244     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Nociception (orphanin FQ) high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5′-O-(gamma-thio)-triphosphate binding in rat brain membranes
2. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells
3. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands
4. Constitutive activation of the d-opioid receptor by mutations in transmembrane domains III and VII
5. Regulation of adenylyl cyclase-coupled beta adrenergic receptors
6. 2C receptor systems
7. Interaction of ligands with the opiate receptors of brain membranes: Regulation by ions and nucleotides
8. A selective agonist for central cannabinoid receptor inhibits mitogen-activated protein-kinase activation stimulated by insulin-like growth factor. 1. Evidence for a new model of receptor ligand interactions
9. Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization
10. Two distinct pathways for cAMP-mediated down-regulation of the beta2-adrenergic receptor. Phosphorylation of the receptor and regulation of its mRNA level
11. Inverse agonist activity of β-adrenergic antagonists
12. Opiate receptor binding affected differentially by opiates and opioid peptides
13. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins
14. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: Thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand
15. Multiple states of opioid receptors may modulate adenylate cyclase in intact neureblastoma x glioma hybrid cells
16. ICI 174864 a highly selective antagonist for the opioid delta-receptor
17. A ternary complex model explains the agonist-specific binding properties of adenylate coupled β-adrenergic receptor
18. Inverse agonism at G-protein coupled receptors: (patho)Physiological relevance and implications for drug discovery
19. Effect of different G protein-coupled receptor kinases on phosphorylation and desensitization of the alpha1B-adrenergic receptor
20. 2, adrenergic receptor. Evidence for ligand specific conformational changes
21. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation
22. Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: Evidence from homologous versus heterologous binding analysis
23. Phosphorylation sites on two domains of the beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization
24. A constitutively active mutant thyrotropin-releasing hormone receptor is chronically down-regulated in pituitary cells: Evidence using chlordiazepoxide as a negative antagonist
25. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the κ-opioid receptor
26. Adrenergic receptors as models for G protein coupled receptors
27. 3H]senktide and [125I-MePhe7]neurokinin B, and is responsive to tachykinin peptide agonists
28. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells
29. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
30. Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists
31. Assessment of a ternary model for the binding of agonists to neurohumoral receptors
32. A three-state receptor model of agonist action
33. G protein coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signalling and desensitization
34. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins
35. 1 receptor antagonists
36. Beta-arrestin: A protein that regulates beta-adrenergic receptor function
37. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells
38. Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists
39. 2-adrenoceptor green fluorescent protein fusion proteins
40. Inverse agonism and the regulation of receptor number
41. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors
42. Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts
43. Expression, purification and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide. Large scale purification of functionally active G-protein coupled receptor produced in Sf9 cells
44. Guanine nucleotide-mediated inhibition of opioid agonist binding. Modulatory effect of ions and receptor occupancy
45. Desensitization and internalization of the m2 muscarinicacetylcholine receptor are directed by independent mechanisms
46. 3]opiate agonist binding by divalent cations
47. Opiate agonist and antagonists discriminated by receptor binding in brain
48. Opiate receptor: Demonstration in nervous tissue
49. Export from endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the δ opioid receptor
50. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist
51. Protein kinases that phosphorylate activated G protein-coupled receptors
52. A mutation changes selectivity and transmembrane signaling preference of the neurokinin-1 receptor
53. Agonist-antagonist interactions at angiotensin receptors: Application of a two state model
54. Bremazocine: A potent, long-acting opiate kappa-agonist
55. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding
56. 2-adrenergic receptors
57. 11]substance P(7-11), a tritiated septide-like peptide, in Chinese hamster ovary cells expressing human neurokinin-1 receptors and in rat submandibular glands
58. 2-adrenergic receptor: Pharmacological creation of a phenotype in transgenic mice
59. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor
60. Constitutively active G protein-coupled receptors: Potential mechanisms of receptor activation
61. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: Development of a class of potent and highly delta-selective peptide antagonists
62. The TIPP opioid peptide family: Development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists
63. Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics
64. s interactions: Evidence for multiple receptor conformations
65. Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation
66. Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a model
67. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors
68. The cubic ternary complex occupancy model. I. Model description
69. 2-dopamine receptor of the anterior pituitary gland
70. Sodium regulation of opioid agonist binding is potentiated by pertussis toxin